Navigation Links
Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus
Date:11/9/2010

ific body systems after treatment with epratuzumab.  Improvements were particularly prominent in cardiorespiratory and neuropsychiatric systems in which symptom improvements are often difficult to achieve.

These results demonstrated that in a patient population with predominantly high or severe disease activity, differences in responder rates between the epratuzumab 600mg weekly and 1200mg every other week groups, and the placebo group was observed as early as week 12, with the emergence of improvements apparent in week 8.

In two previous phase II randomized controlled trials, epratuzumab treatment resulted in clinically meaningful reduced disease activity, improved health-related quality of life (HRQoL) measurements and reduced reliance on corticosteroids compared to placebo treatment in patients with active moderate and severe SLE.

"We are pleased by the repeated consistency of symptom improvement demonstrated by epratuzumab in all our clinical studies to date and we look forward to confirming these results in our phase 3 studies due to start later this year," said Prof. Dr. Iris Loew-Friedrich, Chief Medical Officer of UCB. She added, "Achieving a BILAG improvement, especially at an early timepoint seen in EMBLEM™, is a hopeful sign of the drug's future potential."

Epratuzumab is a humanized monoclonal antibody targeting CD22 and modulating B cell activity.  Although the exact role of CD22 is not fully understood, it is considered to be a regulator of B cell function. B cells are known to contribute to SLE by producing antibodies against the body's own cells and tissues, causing the immune system to turn on itself, resulting in inflammation and tissue damage. Epratuzumab is an anti-B-cell therapeutic, because of its ability to modulate B cell function without depleting a large portion of these lymphocytes.

* This study was not powered to detect statistical differences between treatment arms (p values were no
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015   Cepheid (Nasdaq: CPHD ) today ... 2015 second quarter ended June 30, 2015 on Thursday, ... The Company will host a management presentation ... 2015, to discuss the results.  To access the live ... at least 15 minutes before the scheduled start time ...
(Date:7/6/2015)... DIEGO , July 6, 2015  OncoSec Medical ... DNA-based intratumoral cancer immunotherapies, today announced the appointment of ... position of Vice President of Market Development, effective July ... responsible for evaluating, designing, and executing on the company,s ... "I,m very excited to welcome Joann to ...
(Date:7/5/2015)... 2015 Nihon University is pleased to ... Medical-Engineering Collaboration "Medicine Definitely Jumps Up with 8K" ... Tokyo, Japan . Many experts ... will present their achievements and future prospects on ... produced with 8K technology. (Documentation: ...
Breaking Medicine Technology:OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3
... LONDON, March 19, 2007-AstraZeneca today announced that ... results from the ARISE (Aggressive Reduction of ... which studied,AGI-1067, an investigational anti-atherosclerotic agent with,antioxidant ... disease (CAD). ,The ARISE trial did not ...
... /PRNewswire-FirstCall/ --,Nuvelo, Inc. today announced that clinical data ... MACE)/TIMI 32 Phase,2 trial looking at recombinant nematode ... coronary syndromes,(NSTE-ACS) will be presented in a V-poster ... Session taking place in New,Orleans, LA, March 24-27, ...
Cached Medicine Technology:Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet,Primary Endpoint 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 3
(Date:7/6/2015)... ... July 06, 2015 , ... ... Spa industries, announces the return of its complimentary educational webinar series ... medical business leaders creates success for their clients through targeted marketing, sales, digital ...
(Date:7/6/2015)... Beach, Virginia (PRWEB) , ... July 06, 2015 ... ... States choose fat-reduction procedures each year for aesthetic reasons, which is why liposuction ... country. For a particular demographic, however, fat reduction has become more than a ...
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud to announce ... Teaching Award on behalf of the department of Family Practice. , “This award is ... be practicing in. The technology is changing so rapidly and we are also developing ...
(Date:7/6/2015)... ... July 06, 2015 , ... doTERRA, the leading global ... executive management team. Most recently, Jowers held the position as Director of the Hinckley ... After spending a decade building the institute, Jowers states that he was ready for ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... redesigned site allows newly-diagnosed cancer patients, caregivers and medical professionals to chat with ... survived the same cancer. , “Receiving a cancer diagnosis is often the most ...
Breaking Medicine News(10 mins):Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2
... UPTON, NY - A new study by scientists at the ... Norway suggests that the benefits of moderately increased exposure to ... against the lethal effects of many forms of cancer and ... cancer in populations deficient in vitamin D. The study will ...
... activate abnormally in malignant cells , , MONDAY, Jan. 7 (HealthDay ... genes that play a role in cell division, and ... of those genes show an abnormal pattern of activation in ... issue of the Proceedings of the National Academy of ...
... University Center for Clinical and Translational Science (CCTS) has ... Eight Rockefeller researchers will each receive $25,000 from the ... if successful, might lead to clinical trials. The CCTS ... established through funds from a Clinical and Translational Science ...
... caused by aging, can also be caused by pesticides ... that trichloroethylene (TCE) is a risk factor for parkinsonism, ... Parkinsons disease. TCE is a chemical widely used in ... water and soil due to runoff from manufacturing sites ...
... experts are split on the need for supplements , , MONDAY, ... D -- sourced through sunlight, some foods and supplements ... such as heart attack and stroke, U.S. researchers report. , ... Heart Study included 1,739 people, average age 59, living in ...
... suffering from a form of asphyxia at birth have ... a lifetime of debilitating and costly health complications, according ... , The findings, which appear today in the January ... technique, that better availability and placement of CoolCaps within ...
Cached Medicine News:Health News:More sun exposure may be good for some people 2Health News:More sun exposure may be good for some people 3Health News:Team Finds 118 Genes That Might Play Role in Cancer 2Health News:Rockefeller University's Center for Clinical and Translational Science funds pilot studies 2Health News:Trichloroethylene is a risk factor for parkinsonism 2Health News:Trichloroethylene is a risk factor for parkinsonism 3Health News:Low Vitamin D Linked to Heart Risk 2Health News:Low Vitamin D Linked to Heart Risk 3Health News:Better access to cool caps improves outcomes, lowers cost of treating asphyxia in newborns 2
... an enzymatic cleanser for automated and semi-automated ... 475ml bottle has a flip-top spout for ... that require manual addition of an enzyme ... of this product. The shelf life of ...
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
An environmentally-safe, CN-free lytic reagent designed for use on the Abbott CELL-DYN® 1800 three-part differential hematology analyzer....
... is a nucleated red blood cell (nRBC) control ... Coulter LH 750/LH 755 hematology analyzer in its ... for the Coulter LH 750/LH 755. nRBC-Chex for ... cap-pierceable vials. nRBC-Chex for LH has a 75-day ...
Medicine Products: